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Objectives: Mycobacterium abscessus is innately resistant to a variety of drugs thereby limiting therapeutic op-
tions. Bacterial resistance to aminoglycosides (AGs) is conferred mainly by AG-modifying enzymes, which often
have overlapping activities. Several putative AG-modifying enzymes are encoded in the genome ofM. abscessus.
The aim of this studywas to investigate themolecular basis underlying AG resistance inM. abscessus.
Methods: M. abscessus deletion mutants deficient in one of three genes potentially involved in AG resistance,
aac(20), eis1 and eis2, were generated by targeted gene inactivation, as were combinatorial double and triple de-
letionmutants. MICs were determined to study susceptibility to a variety of AG drugs and to capreomycin.
Results: Deletion of aac(20) increased susceptibility of M. abscessus to kanamycin B, tobramycin, dibekacin and
gentamicin C. Deletion of eis2 increased susceptibility to capreomycin, hygromycin B, amikacin and kanamycin
B. Deletion of eis1 did not affect drug susceptibility. Equally low MICs of apramycin, arbekacin, isepamicin and
kanamycin A for WT and mutant strains indicate that these drugs are not inactivated by either AAC(20) or Eis
enzymes.
Conclusions: M. abscessus expresses two distinct AG resistance determinants, AAC(20) and Eis2, which confer
clinically relevant drug resistance.
Introduction
Mycobacterium abscessus is a rapid growing mycobacterium of
increasing medical importance. This emerging pathogen causes
bronchopulmonary infections in individuals with cystic fibrosis1
and chronic pulmonary disease, such as pneumoconiosis and
bronchiectasis.2 It also causes severe infections following surgery,
transplantation, tattooing and mesotherapy.3–8 Treatment of an
M. abscessus infection is difficult due to the bacteria’s high degree
of intrinsic resistance to chemotherapeutic agents.9 The pathogen
is naturally resistant to many major classes of antibiotics used for
the treatment of Gram-positive and Gram-negative bacterial in-
fections, such as b-lactams, aminoglycosides (AGs) (kanamycin B,
gentamicin C) andmacrolides (erythromycin). In addition, it is also
resistant to first-line TB drugs, for instance isoniazid and rifampicin.
M. abscessus has been called an antibiotic nightmare since treat-
ment options againstM. abscessus infection aremore limited than
for Mycobacterium tuberculosis infection.10 While no standard
treatment recommendations for pulmonary M. abscessus infec-
tions have yet been established, current guidelines propose
administration of an oral macrolide (clarithromycin or azithromy-
cin) for clinical isolates susceptible tomacrolides and the intraven-
ous AG amikacin in combination with a parenteral b-lactam
antibiotic, cefoxitin or imipenem.11 AGs andmacrolides inhibit pro-
tein biosynthesis by binding to the small and large ribosomal sub-
unit, respectively. Clinically acquired pan-AG and pan-macrolide
resistance has been attributed to mutations in ribosomal RNA
genes rrs and rrl, coding for 16S and 23S rRNA, respectively. Owing
to the presenceof a single ribosomal RNA (rrn) operon, correspond-
ing resistance mutations have readily been observed inM. absces-
sus.12–14 However, distinct mechanisms have been proposed to be
responsible for innate AG resistance inM. abscessus.9,15
AG antibiotics form a group of hydrophilic molecules, consist-
ing of a characteristic, central aminocyclitol linked to one or
more amino sugars by pseudoglycosidic bond(s). They inhibit
prokaryotic protein biosynthesis by binding to the A-site of the
16S rRNA. AGs are active against a wide range of aerobic Gram-
negative bacilli, staphylococci and mycobacteria. Resistance to
AGs is due to low uptake, increased efflux, target modification
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or enzyme-mediated drugmodification. Originally isolated from
microorganisms (mainly Streptomyces spp.), semi-synthetic de-
rivatives of AGs have been generated to improve the pharmaco-
logical properties of the drugs and to overcome bacterial
resistance mechanisms.16 The semi-synthetic drug amikacin is
a cornerstone of M. abscessus infection therapy, whereas other
AGs are not frequently used. M. abscessus genome annotation
suggests the presence of various AG-modifying enzymes such
as AG phosphotransferases, AG nucleotidyltransferases and AG
acetyltransferases (AACs).17 The individual contribution of these
genes toM. abscessus AG susceptibility cannot be predicted reli-
ably due to overlapping specificities.
Elucidation of gene functions, drug target and host–pathogen
interaction heavily relies on the generation of isogenic mutants.
Usually, antibiotic resistance markers are used for the primary se-
lection of transformants. Tools for genetic manipulation of myco-
bacteria in general, and M. tuberculosis in particular, have been
developed during the past two or three decades.18 In contrast,
geneticmanipulation ofM. abscessus has been reported to be very
difficult and attempts have often been unsuccessful,19–21 al-
though some progress has been made.22–25 We recently de-
veloped genetic tools for M. abscessus26 and have now exploited
them for elucidating intrinsic AG resistance mechanisms in the
M. abscessus ATCC 19977 type strain. We particularly addressed
the role of putative AACs in M. abscessus AG and capreomycin re-
sistance. We generated single, double and triple mutants of
M. abscessus by targeted deletion of three genes potentially
involved in AG resistance and characterized those mutants by
phenotypic drug susceptibility testing. Interestingly, a double mu-
tant proved to be susceptible to a wide variety of AGs and to the
peptide antibiotic capreomycin.
Materials and methods
Bacterial strains and media
The Escherichia coli laboratory strain XL1-Blue MRF0 (Stratagene,
Switzerland) and ER2925 dam#, dcm#were used for cloning and propaga-
tion of plasmids. The strains were grown in LB medium containing one of
the antibiotics: ampicillin (120mg/L), kanamycin A (50mg/L), apramycin
(50mg/L) or hygromycin B (100mg/L). Antibiotics (Sigma–Aldrich,
Switzerland) were dissolved in water according to the manufacturer’s rec-
ommendations and stored as a stock solution until usage.
M. abscessus ATCC 19977 was grown in Middlebrook 7H9-OADC-Tween
80 or LB containing one of the antibiotics, if required: kanamycin A (50mg/L),
apramycin (50mg/L) or isoniazid (32mg/L). For preparation of electrocompe-
tent cells two cell culture flasks each containing 200mLof 7H9-OADC-Tween
80 were inoculated 1:100, incubated at 37C and gently shaken daily. When
OD600 reached 0.4–0.8, cultureswere set on ice for 90min. Bacteriawere har-
vested by centrifugation and repeatedly resuspended in ice-cold glycerol
(10% v/v)while gradually reducing the volume.27 Finally, bacteriawere resus-
pended in 2mLof glycerol (10% v/v) andeither frozen in liquid nitrogenor dir-
ectly used for electroporation, as we recently described.26 Genomic DNAwas
isolated by phenol/chloroform/isoamyl alcohol extraction, as described
previously.28
Generation of vectors
Theapramycin resistance cassette fromplasmid pSET15229was PCRampli-
fied (primers Apr_F and Apr_R) (see Table S1, available as Supplementary
data at JACOnline, for list of primers) and cloned as a 1 kbp SpeI fragment
into SpeI-digested plasmid pMV36130 to result in plasmid pMV361-apr.
An M. tuberculosis katG fragment (2.8 kbp) was PCR amplified (primers
KatG_F and KatG_R) and cloned into pGEM-T-easy to result in pGEM-T-katG.
Subsequently, the 2.8 kbp SwaI-katG-HpaI fragment was cloned into HpaI-
linearized pMV361-apr to result in pMV361-apr-katG. Removal ofmycobac-
teriophage attP/int from plasmid pMV361-apr-katG by XbaI excision and
self-ligation of the vector backbone resulted in the prototype suicide vector
pSE-apr-katG intowhich flanking regions of the target geneswere cloned.
Disruption of MAB_4395 [aac(20)] in M. abscessus
A 1.6 kbp NdeI/NheI fragment of M. abscessus ATCC 19977 from position
4477184 to 4478794 comprising the 50 flanking sequence and a 1.5 kbp
NheI/MluI fragment from position 4479125 to 4480674 comprising the
30 flanking sequence of MAB_4395 [aac(20)] were PCR amplified (primers
4395_UP_F, 4395_UP_R and 4395_DW_F, 4395_DW_R) using genomic DNA
fromM. abscessusATCC19977. Subsequently, fragmentswere ligated step-
wise into saving vector pMCS5 with respective enzymes resulting in sub-
cloning vector pMCS5-MAB_4395. The region comprising 50 and 30 flanking
sequences of aac(20)was cut out with StuI and cloned into HpaI-linearized
pSE-apr-katG vector to result in knockout vector pSE-Daac(20). The aac(20)
allele was deleted from the M. abscessus ATCC 19977 chromosome using
apramycin for positive and isoniazid for negative selection. Deletion of
aac(20) was confirmed by Southern blot analysis of Van91I-digested gen-
omic DNA with a 0.3 kbp 50 aac(20) probe amplified with primers P_4395_F
and P_4395_R. A 2.2 kbp fragment from M. abscessus ATCC 19977 from
position 4477131 to 4479338 spanning the entire aac(20) gene was ampli-
fiedwith primers C_4395_F and C_4395_R and cloned into HindIII-digested
pMV361 vector to result in pMV361-aac(20) complementation vector. M.
abscessus Daac(20)was transformedwith pMV361-aac(20) and control vec-
tor pMV361, respectively. Genetic complementation was confirmed by
Southern blot analysiswith the same50 aac(20) probe.
Disruption of MAB_4124 (eis1) in M. abscessus
A 1.6 kbp ApaI/NdeI fragment of M. abscessus ATCC 19977 from position
4187416 to 4189052 comprising the 50 flanking sequence and a 1.7 kbp
NdeI/NheI fragment from position 4189857 to 4191580 comprising the
30 flanking sequence of MAB_4124 (eis1) were PCR amplified (primers
4124_UP_F, 4124_UP_R and 4124_DW_F, 4124_DW_R) using genomic DNA
from M. abscessus ATCC 19977. Fragments were stepwise cloned with cor-
responding enzymes into saving vectors and subsequently into NotI/XbaI-
digested vector pSE-apr-katG to result in knockout vector pSE-Deis1. The eis1
allele was deleted from the M. abscessus ATCC 19977 chromosome using
apramycin (positive) and isoniazid (negative) selection. Deletion was con-
firmed by Southern blot analysis using Van91I-digested genomic DNA and a
0.3 kbp 50 eis1 fragment amplifiedwith primers P_4124_F and P_4124_R.
Disruption of MAB_4532c (eis2) in M. abscessus
A 1.8 kbp HpaI/Pfl23II fragment ofM. abscessus ATCC 19977 from position
4612843 to 4614693 comprising the 50 flanking sequence and a 1.5 kbp
PacI/Pfl23II fragment from position 4615391 to 4616869 comprising the
30 flanking sequence of MAB_4532c (eis2) were PCR amplified (primers
4532c_UP_F, 4532c_UP_R and 4532c_DW_F, 4532c_DW_R) using genomic
DNA from M. abscessus ATCC 19977. Fragments were stepwise cloned into
vector pSE-apr-katG resulting in knockout vector pSE-Deis2. The eis2 allele
was deleted from the M. abscessus ATCC 19977 chromosome using apra-
mycin (positive) and isoniazid (negative) selection. Deletion was confirmed
by Southern blot analysiswith Van91I-digested genomic DNAand a 0.3 kbp
50 eis2 probe amplified with primers P_4532c_F and P_4532c_R. For com-
plementation a 1.3 kbp fragment from M. abscessus ATCC 19977 (position
4614320–4615651) spanning the entire eis2 gene was PCR amplified (pri-
mers C_4532c_F, C_4532c_R) and cloned via HindIII into pJB-apr vector to
result in pJB-apr-eis2 complementation vector. M. abscessus Deis2 was
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transformed with pJB-apr-eis2 and control vector pJB-apr, respectively.
Genetic complementationwas confirmed by Southern blot analysis.
MIC assays
Kanamycin B, tobramycin, dibekacin, arbekacin, gentamicin C [C1 (,45%),
C2 (,35%) and C1a (,30%)], isepamicin, amikacin, kanamycin A, apramy-
cin, streptomycin, hygromycin B and capreomycin were bought from
Sigma–Aldrich. Antibiotics were dissolved in water according to the manu-
facturer’s recommendations, were filter sterilized, aliquoted into stock solu-
tions and stored at –20C. MIC determination for M. abscessus strains was
done according to CLSI guidelines31 and basically as we previously
described.26
Results
Targeted inactivation of putative AG resistance genes
of M. abscessus
Genomeannotation,17 genome analysis andAG drug susceptibility
testing15 suggest the presence of several putative AACs in
M. abscessus. ORF MAB_4395 is annotated as a putative AG 20-N-
acetyltransferase [aac(20)],17 while MAB_4124 and MAB_4532c
showhomology toeis. Eis (enhanced intracellular survival) proteins
are found in a variety of mycobacterial and non-mycobacterial
species.32,33 Overexpression of Eis (Rv2416c) confers increased
kanamycin resistance on M. tuberculosis.34 M. abscessus
MAB_4124 is the closest homologue of M. tuberculosis Rv2416c
(33% identity), which we therefore name eis1. Interestingly, a se-
cond Eis homologue encoded by MAB_4532c is present in the M.
abscessus genome. In a phylogenetic tree constructed from 29 Eis
homologues,33MAB_4532c (whichwenameEis2) is clusteredwith
Eis homologues from the non-mycobacterial clade instead of the
mycobacterial group, e.g. M. abscessus Eis2 shows 23% identity to
Anabaena variabilis Eis. We addressed the role of the three acetyl-
transferases in M. abscessus AG resistance by engineering and
characterizing corresponding unmarked deletion mutants in the
M. abscessusATCC 19977 type strain.
Flanking fragments of the target genes aac(20), eis1 and eis2
were cloned into plasmid pSE-apr-katG to result in suicide vectors
pSE-Daac, pSE-Deis1 and pSE-Deis2, respectively. These flanking
fragments enable homologous recombination of the suicide vec-
tor. The apramycin resistance cassette of the vector backbone fa-
cilitates selection of single crossover transformants resulting from
vector integration by intermolecular homologous recombination
at the target locus. Catalase–peroxidase KatG, the activator of the
TB prodrug isoniazid,35 serves as a negative selectable marker
since it sensitizes M. abscessus to isoniazid. Expression of KatG fa-
cilitates screening for deletion mutants resulting from resolving
the integration of the suicide vector by a second intramolecular
homologous recombination.26 Electrocompetent M. abscessus
were transformed and apramycin selection and Southern blot
analysis were applied to identify single crossover transformants.
Subsequently, isoniazid counterselection and Southern blot ana-
lysis were applied for the identification ofM. abscessusDaac(20),M.
abscessus Deis1 and M. abscessus Deis2 mutants (Figure 1).
Deletion mutants showing a phenotype [M. abscessus Daac(20)
and M. abscessus Deis2] were transformed with single copy, i.e.
pMV361-based complementation and control vectors, respectively
(see Table 1 for list of strains and Table 2 for list of plasmids).
Furthermore, single deletion mutants served as parental strains
for construction of double deletion mutants by transformation
with a second targeting vector. Double deletion mutants, M.
abscessus Daac(20) Deis1, M. abscessus Daac(20) Deis2 and M.
abscessus Deis1 Deis2, were confirmed by Southern blot analyses.
Finally, by transformation of pSE-Daac(20) into M. abscessus Deis1
Deis2, the triple mutant M. abscessus Daac(20) Deis1 Deis2 was
constructed (Figure 2).
Drug susceptibility testing of M. abscessus mutant
strains
Drug susceptibility ofM. abscessus strains towards a variety of struc-
turally similar 4,6-disubstituted AGs (Figure 3) was tested in
CAMHB. In addition, drug susceptibility to structurally atypical AGs
apramycin, hygromycin B and streptomycin and to the peptide
antibiotic capreomycin (also inhibiting protein biosynthesis by inter-
action with the 16S rRNA A-site) was determined. Growth was
judged after 3, 5, 7 and 12days of incubation and the MICs were
determined. Themedian MIC values on day 5 are shown in Table 3.
The MIC values read at all timepoints are shown in Table S2. A var-
iety of mutant phenotypes was observed. Deletion of aac(20)
increased susceptibility of M. abscessus to kanamycin B (64-fold),
tobramycin (32-fold), dibekacin (16-fold) and gentamicin C (4-fold).
Deletion ofaac(20)did not affectMICs of arbekacin, isepamicin, ami-
kacin, kanamycin A, apramycin, streptomycin, hygromycin B and
capreomycin (Table 3). The tobramycin, dibekacin and gentamicin
C WT phenotype was restored upon transformation with the com-
plementation vector pMV361-aac(20), but not by transformation
with the backbone control vector pMV361 (Table S2). The presence
of a kanamycin resistance cassette [aph(30)] in the backbone of the
complementation vector interfered with susceptibility testing for
kanamycin A and B and MICs of these compounds are therefore
not reported. Deletion of eis1 did not result in a detectable pheno-
type; MICs of none of the tested antibiotics were altered. Owing to
the absence of a phenotype, no complementation vector was con-
structed. Deletion of eis2 increased susceptibility ofM. abscessus to
several AGs. However, the susceptibility pattern of M. abscessus
Deis2 clearly differed from that ofM. abscessusDaac(20). Deletion of
eis2 increased susceptibility to kanamycin B (4-fold), amikacin
(8-fold), hygromycin B (16-fold) and capreomycin (32-fold).
Deletion of eis2 did not affect susceptibility to tobramycin, dibeka-
cin, arbekacin, gentamicin C, isepamicin, kanamycin A, apramycin
and streptomycin. Transformation of the Deis2 mutant with the
complementation vector pJB-apr-eis2, but not with the vector
backbone pJB-apr, restored WT MICs of amikacin, hygromycin
B and capreomycin (Table S2). The presence of the apramycin re-
sistance cassette in the backbone of the complementation vector
interferedwith susceptibility testing for kanamycin (A and B), tobra-
mycin, dibekacin, gentamicin C and apramycin, and therefore MIC
values of these antibiotics are not reported. Double mutant
M. abscessus Daac(20) Deis1 had the same phenotype as the
Daac(20) single mutant. Double mutant M. abscessus Deis1 Deis2
had the same phenotype as the Deis2 single mutant. The
M. abscessus Daac(20) Deis2 double mutant showed increased sus-
ceptibility to kanamycin B, tobramycin, dibekacin, gentamicin C,
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Figure 1. Genotypic analyses of M. abscessus deletion mutants. (a) General schematic drawing of genotypes and recombination events. (b) Southern
blot analysis confirms the deletion of aac(20) (MAB_4395) from the genome of M. abscessus. Genomic DNA of M. abscessus ATCC 19977 (lane 1),
M. abscessus transformant with pSE-Daac(20) targeting vector prior to (lane 2) and after KatG-dependent isoniazid counterselection (lane 3) and after
transformation of counterselected mutant with pMV361-aac(20) complementation vector (lane 4) was digested with Van91I and probed with a
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amikacin, hygromycin Band capreomycin,whereasMICs of arbeka-
cin, isepamicin, kanamycin A, apramycin and streptomycin were
not altered. Thus, the phenotype of the Daac(20) Deis2 double mu-
tant is a combination of the phenotype of the single mutants. The
phenotype of the triple Daac(20) Deis1 Deis2mutant was similar to
the phenotype of the Daac(20) Deis2 double mutant. Together,
these data indicate a distinct role of aac(20) and of eis2 in intrinsic
AG and capreomycin resistance in M. abscessus. Notably, AAC(20)
and Eis2 prevent antibacterial effects of different subsets of AGs.
The only exception is kanamycin B, which is modified by both
AAC(20) and Eis2.However, the deletion of aac(20)hada stronger ef-
fect on kanamycin B susceptibility than the deletion of eis2 (64-fold
versus 4-fold). AAC(20) is more influential than Eis2, since the MIC
for the double deletion mutant is not further decreased as com-
pared with the aac(20) deletion mutant. Deletion of eis1 from the
genome of the Daac(20) Deis2 mutant did not further increase AG
susceptibility, indicating a negligible role of Eis1 in M. abscessus in-
trinsic AG resistance, even in an aac(20) eis2 double deletion
mutant.
Discussion
M. abscessus is a pathogen of increasing medical importance, par-
ticularly in individuals with chronic pulmonary disease. The high
level of intrinsic resistance to many classes of antibiotics restricts
antibiotic therapy.9 Genome annotation,17 susceptibility testing
and biochemical assays predicted a role for 20-N-acetyltransferase
in M. abscessus AG resistance.15 A candidate gene eventually re-
sponsible for the increased MIC levels of 20-amino-AGs, MAB_4395
[aac(20)] was inactivated by targeted gene deletion. Comparison of
WT andmutant strains by phenotypic susceptibility testing demon-
strated a decreased MIC for the mutant of a variety of drugs char-
acterized by a 20-amino group (kanamycin B, tobramycin,
dibekacin, gentamicin C). Kanamycin A,which differs fromkanamy-
cin B by a single structural feature (20-OH group instead of a 20-
amino group), has a lower MIC for the WT strain than kanamycin
B and its MIC is not further decreased by aac(20) deletion. These
data corroborate the hypothesis that MAB_4395 encodes a func-
tional AG 20-N-acetyltransferase, which renders M. abscessus
fragment from the 50 aac(20) flanking region. Based on M. abscessus genome annotation and vector sequence, the pattern is consistent with hybrid-
ization to a 2.5 kbp fragment of the WT parental strain, to the 2.1 and 2.5 kbp fragments after site-specific homologous recombination (single cross-
over; sco), to a 2.1 kbp fragment of the M. abscessus Daac(20) mutant (D) and to the 2.1 and 11.2 kbp fragments of the M. abscessus Daac(20)
pMV361-aac(20) complemented mutant strain (C). (c) Southern blot analysis confirms the deletion of eis1 (MAB_4124) from the genome of
M. abscessus. Genomic DNA ofM. abscessus ATCC 19977 (lane 1),M. abscessus transformant with pSE-Deis1 targeting vector prior to (lane 2) and after
KatG-dependent isoniazid counterselection (lane 3) was digested with Van91I and probed with a fragment from the 50 eis1 flanking region. Based on
M. abscessus genome annotation and vector sequence, the pattern is consistent with hybridization to a 5.6 kbp fragment of the WT parental strain, to
the 4.4 and 7.8 kbp fragments after site-specific homologous recombination (sco) and to a 10.4 kbp fragment of the M. abscessus Deis1 mutant (D).
(d) Southern blot analysis confirms the deletion of eis2 (MAB_4532c) from the genome of M. abscessus. Genomic DNA of M. abscessus ATCC 19977
(lane 1), M. abscessus transformant with pSE-Deis2 targeting vector prior to (lane 2) and after KatG-dependent isoniazid counterselection (lane 3)
and after transformation of counterselected mutant with pJB-apr-eis2 complementation vector (lane 4) was digested with Van91I and probed with
a fragment from the 50 eis2 flanking region. Based on M. abscessus genome annotation and vector sequence, the pattern is consistent with hybridiza-
tion to a 1.1 kbp fragment of the WT parental strain, to the 1.1 and 3.4 kbp fragments after site-specific homologous recombination (sco), to a
4.8 kbp fragment of the M. abscessus Deis2mutant (D) and to the 4.8 and 10.3 kbp fragments of the M. abscessus Deis2 pJB-apr-eis2 complemented
mutant strain (C).
Table 1. Strains used in this study
Strain Description Source
E. coli XL1-Blue MRF’ cloning and propagation of plasmids Stratagene
E. coli ER2925 dam#, dcm# cloning and propagation of plasmids with methylase susceptible
restriction enzymes
New England BioLabs
M. abscessus ATCC 19977 M. abscessus type strain Ripoll et al. 200917
M. abscessus Daac(20) M. abscessus aac(20) deletion mutant; derivative of M. abscessus ATCC 19977 this study
M. abscessus Deis1 M. abscessus eis1 deletion mutant; derivative ofM. abscessus ATCC 19977 this study
M. abscessus Deis2 M. abscessus eis2 deletion mutant; derivative ofM. abscessus ATCC 19977 this study
M. abscessus Daac(20) Deis1 M. abscessus aac(20) eis1 double deletion mutant; derivative of M. abscessus Deis1 this study
M. abscessus Daac(20) Deis2 M. abscessus aac(20) eis2 double deletion mutant; derivative of M. abscessus Daac(20) this study
M. abscessus Deis1 Deis2 M. abscessus eis1 eis2 double deletion mutant; derivative ofM. abscessus Deis2 this study
M. abscessus Daac(20)
Deis1 Deis2
M. abscessus aac(20) eis1 eis2 triple deletion mutant; derivative ofM. abscessus Deis1 Deis2 this study
M. abscessus Daac(20)
pMV361-aac(20)
M. abscessus aac(20)mutant transformed with complementation vector pMV361-aac(20) this study
M. abscessus Daac(20) pMV361 M. abscessus aac(20)mutant transformed with pMV361 control vector this study
M. abscessus Deis2 pJB-apr-eis2 M. abscessus Deis2mutant transformed with complementation vector pJB-apr-eis2 this study
M. abscessus Deis2 pJB-apr M. abscessus Deis2mutant transformed with control vector pJB-apr this study
Figure 1. Continued
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relatively resistant to several AGs with a 20-amino group. Amikacin
is protected from AAC(20) modification due to the presence of an
OH group at position 20. Actually, amikacin is a derivative of kana-
mycin A, but with an L-hydroxyaminobutyryl amide (L-HABA) side
chain at position 1 of the 2-deoxystreptamine core. Tobramycin (30-
deoxy-kanamycin B) is inert tomodification by 30-phosphotransfer-
ases, but susceptible tomodification by AAC(20). This is indicated by
the observation that the kanamycin B and tobramycin MICs are
similarly decreased for the Daac(20) mutant strain as compared
with the parental strain. Since tobramycin is not a substrate for the
30-AG-phosphotransferase [which is encoded on the backbone of
the complementation vector pMV361-aac(20)], restoration of the
tobramycin phenotype could be addressed by transformation with
the complementation vector. Phenotypic complementation was
observed, indicating that deletion of aac(20) is responsible for
increased tobramycin susceptibility of themutant. TheMIC of arbe-
kacin is similarly low for theWT strain and theDaac(20)mutant and
similar to the MIC of dibekacin for the Daac(20) mutant, while the
dibekacin MIC for the WT strain is much higher. Dibekacin
(30,40-dideoxy-kanamycin B) differs from arbekacin at position 1 of
Table 2. Plasmids used in this study
Plasmid Description; selectable marker Source
pMV361 integrative E. coli/mycobacterial shuttle vector; KanR Stover et al. 199130
pSET152 Streptomyces vector with apramycin resistance gene (aac(3)IV), template for apr amplification; AprR Wilkinson et al. 200229
pGEM-T-easy PCR saving vector; AmpR Promega
pMCS5 general cloning vector; AmpR MBio
pGEM-T-katG intermediate vector for katG subcloning; AmpR this study
pMV361-apr integrative E. coli/mycobacterial shuttle vector; KanR, AprR this study
pMV361-apr-katG derivative of pMV361-apr containingM. tuberculosis katG; KanR, AprR, INHS this study
pSE-apr-katG derivative of pMV361-apr-katG deleted for mycobacteriophage integrase int and attP; intermediate
vector used for cloning of Daac(20), Deis1 and Deis2 alleles; KanR, AprR, INHS
this study
pMCS5-MAB_4395 intermediate vector containing aac(20) flanking regions; AmpR
pSE-Daac(20) suicide vector; derivative of pSE-apr-katG carrying Daac(20) allele; AprR, KanR, INHS this study
pSE-Deis1 suicide vector; derivative of pSE-apr-katG carrying Deis1 allele; AprR, KanR, INHS this study
pSE-Deis2 suicide vector; derivative of pSE-apr-katG carrying Deis2 allele; AprR, KanR, INHS this study
pMV361-aac(20) integrative complementation vector for aac(20), KanR this study
pJB-apr derivative of pMV361 in which the kanamycin resistance cassette was substituted by the apramycin
resistance cassette; AprR
this study
pJB-apr-eis2 integrative complementation vector for eis2; derivative of pJB-apr; AprR this study
KanR, kanamycin resistance cassette; AprR, apramycin resistance cassette; AmpR, ampicillin resistance cassette; INHS, isoniazid susceptibility cassette.
M. abscessus ∆aac(2′)
M. abscessus ∆aac(2′) pMV361-aac(2′)
M. abscessus ∆aac(2′) pMV361
M. abscessus ∆aac(2′) ∆eis2 M. abscessus ∆eis1 ∆aac(2′) M. abscessus ∆eis2 ∆eis1
M. abscessus ∆eis2 ∆eis1 ∆aac(2′)
M. abscessus ∆eis2M. abscessus ∆eis1
M. abscessus ATCC 19977
WT
M. abscessus ∆eis2 pJB-apr-eis2
M. abscessus ∆eis2 pJB-apr












Gentamicin C1 Gentamicin C1a Gentamicin C2
Apramycin Streptomycin Hygromycin B
Figure 3. Structure of 4,6-disubstituted (a–j) and atypical (k–m) AGs used in this study. Black arrows show the 20 groups of the 4,6-distubstituted
AGs (a–j).
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the 2-deoxystreptamine core; there arbekacin carries an L-HABA
chain,which obviously protects fromAAC(20) activity.
Gentamicin C is not a pure compound, but amixture of different
subclasses (C1, C2 and C1a). C-type gentamicin subgroups carry a
20-NH2 group. In contrast, B-type gentamicin carries a 2
0-OH group.
Isepamicin is a derivative of gentamicin B with an L-HABA side
chain at position 1 of the 2-deoxystreptamine core. TheMIC for the
WT strain of isepamicin is lower than that of gentamicin C, while
both compounds have similarly (low) MICs for the Daac(20)
mutant. These findingsmay beexplainedby the enzymaticmodifi-
cation of gentamicin C by the AAC(20) activity present in the WT
strain. Taken together, comparison of the MICs for the WT strain
and the Daac(20)mutant indicates that AAC(20) confers resistance
to drugs carrying a 20-NH2 group, unless position 1 of the 2-deoxy-
streptamine core ismodified with an L-HABA chain (compare dibe-
kacin and arbekacin). Neither deoxygenation at 30 nor di-
deoxygenation at positions 30 and 40 (compare kanamycin B with
tobramycin and dibekacin, respectively) prevent M. abscessus
AAC(20)-mediated drug resistancemechanisms. An approximately
10-fold decrease in the MICs of gentamicin C and tobramycin and
an even higher decrease in the MIC of dibekacin were also seen
upon genetic inactivation ofMycobacterium smegmatis aac(20).36
The M. abscessus Deis1 mutant did not show any resistance
phenotype and therefore does not contribute to AG resistance, at
least not during in vitro growth. Expression studies and biochem-
ical assays would be required to address the physiological and en-
zymatic function of Eis1. Itmay be hypothesized that promoter-up
mutations might increase AG resistance. This hypothesis could
also be addressed by transformation ofWT strains withmulti-copy
vectors containing eis1. However besides AAC(20)-mediated AG re-
sistance, M. abscessus possesses at least a second mechanism of
AG resistance, which is mediated by Eis2. The Deis2 mutant
showed increased susceptibility to the peptide antibiotic capreo-
mycin and to a distinct and more heterogeneous group of
AGs: kanamycin B, amikacin and hygromycin B. Eis proteins of
different origin have been shown to have multiple AG- and
capreomycin-acetylating activities, e.g. M. tuberculosis and
M. smegmatis Eis tri-acetylate neamine in a sequential manner,
first at position 20, then at position 60 and finally at position 1. The
number of acetylations depends on the AG itself, but also on the
biological origin of the enzyme. Up to four acetyl residues may be
transferred to tobramycin byM. tuberculosis Eis andM. smegmatis
Eis, respectively.33,37,38 Hygromycin is mono- and di-acetylated by
M. smegmatis andM. tuberculosis Eis, respectively. Apramycin is di-
acetylated by M. smegmatis, but is not a substrate for M. tubercu-
losis Eis.M. abscessus Eis2 does not inactivate apramycin (identical
MICs for the WT strain and the Deis2 mutant), although this does
not exclude that apramycin is an M. abscessus Eis2 substrate.
Corresponding acetylations might just not affect antibacterial ac-
tivity. A combined application of an AAC(20) inhibitor together with
specific NH2-AGs (e.g. kanamycin B and gentamicin C) could en-
hance the activity of these AGs. Administration of an Eis2 inhibitor
could enhance the activity of capreomycin and amikacin, the latter
being a cornerstone for treatment of M. abscessus infections.39 As
opposed to several 2-deoxystreptamine AGs, streptomycin MICs
for themutant strains remained at the highWTMIC level, pointing
to a distinct streptomycin resistance mechanism in M. abscessus.
Our study demonstrates that apramycin, an AG with little ototox-
icity,40 arbekacin, isepamicin and kanamycin A exhibit excellent
in vitro activities against the M. abscessus ATCC 19977 type strain
and that the activity of these drugs is not affected by AAC(20) and
Eis proteins, respectively. Our data further support MIC determina-
tion of these AGs for a broader set of M. abscessus clinical iso-
lates.15 The results from the suggested in vitro studiesmay provide
a rational basis for designing clinical trials aiming at implementa-
tion of improved treatment regimens against one of the most
drug-resistant pathogens,M. abscessus.
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Table 3. MICs for M. abscessus deletion mutants (all values are medians, on day 5)a,b
Strain
Compound WT Daac(20) Deis1 Deis2 Daac(20) Deis1 Daac(20) Deis2 Deis1 Deis2 Daac(20) Deis1 Deis2
Kanamycin B 8 0.125 8 2 0.125 0.125 1 0.125
Tobramycin 8 0.25 8 4 0.25 0.125 2 0.125
Dibekacin 16 1 16 16 2 1 16 1
Arbekacin 1 0.5 1 1 0.5 0.5 0.5 0.5
Gentamicin C 4 1 4 4 1 1 4 1
Isepamicin 1 1 1 0.5 1 0.5 0.5 0.5
Amikacin 2 2 2 0.25 2 0.25 0.25 0.25
Kanamycin A 1 1 1 0.5 1 0.5 0.5 0.25
Apramycin 0.5 0.5 1 0.5 0.5 0.5 0.5 0.5
Streptomycin 32 32 32 32 32 32 32 32
Hygromycin B 256 256 256 16 256 16 16 16
Capreomycin 128 128 256 4 128 4 4 4
aFor a complete overview of MIC results from three independent experiments judged at days 3, 5, 7 and 12 see Table S2.
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13 Sander P, Böttger EC. Mycobacteria: genetics of resistance and implica-
tions for treatment.Chemotherapy1999;45: 95–108.
14 Wallace RJ, Meier A, Brown BA et al. Genetic basis for clarithromycin
resistance among isolates of Mycobacterium chelonae and
Mycobacterium abscessus. Antimicrob Agents Chemother 1996; 40:
1676–81.
15 Maurer FP, Bruderer VL, Castelberg C et al. Aminoglycoside-modifying en-
zymes determine the innate susceptibility to aminoglycoside antibiotics in
rapidly growingmycobacteria. J Antimicrob Chemother2015;70: 1412–9.
16 Magnet S, Blanchard JS. Molecular insights into aminoglycoside action
and resistance.ChemRev2005;105: 477–98.
17 Ripoll F, Pasek S, Schenowitz C et al. Non-mycobacterial virulence genes
in the genome of the emerging pathogen Mycobacterium abscessus. PLoS
One2009;4: e5660.
18 Lamrabet O, Drancourt M. Genetic engineering of Mycobacterium tuber-
culosis: a review. Tuberculosis (Edinb)2012;92: 365–76.
19 Cortes M, Singh AK, Reyrat JM et al. Conditional gene expression in
Mycobacteriumabscessus. PLoSOne2011;6: e29306.
20 Medjahed H, Reyrat JM. Construction of Mycobacterium abscessus
defined glycopeptidolipidmutants: comparison of genetic tools. Appl Environ
Microbiol2009;75: 1331–8.
21 Pawlik A, Garnier G, Orgeur M et al. Identification and characterization of
the genetic changes responsible for the characteristic smooth-to-roughmor-
photype alterations of clinically persistent Mycobacterium abscessus. Mol
Microbiol2013;90: 612–29.
22 Halloum I, Carrère-Kremer S, BlaiseM et al. Deletion of a dehydratase im-
portant for intracellular growth and cording renders rough Mycobacterium
abscessusavirulent. ProcNatl Acad Sci USA2016;113: E4228–37.
23 Kim YS, Yang CS, Nguyen LT et al. Mycobacterium abscessus ESX-3 plays
an important role in host inflammatory andpathological responses during in-
fection.Microbes Infect2017;19: 5–17.
24 Lefebvre AL, Dubée V, CortesM et al. Bactericidal and intracellular activity
of b-lactams against Mycobacterium abscessus. J Antimicrob Chemother
2016;71: 1556–63.
25 Viljoen A, BlaiseM, de Chastellier C et al.MAB_3551c encodes the primary
triacylglycerol synthase involved in lipid accumulation in Mycobacterium
abscessus.MolMicrobiol2016;102: 611–27.
26 Rominski A, Roditscheff A, Selchow P et al. Intrinsic rifamycin resistance
of Mycobacterium abscessus is mediated by ADP-ribosyltransferase
MAB_0591. J Antimicrob Chemother2017;72: 376–84.
27 Sander P, PapavinasasundaramKG, Dick T et al.Mycobacteriumbovis BCG
recA deletion mutant shows increased susceptibility to DNA-damaging
agents but wild-type survival in a mouse infection model. Infect Immun
2001;69: 3562–8.
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